We aimed to determine the additional value of testing the new B cell-related markers in CSF (FLC metrics and CXCL13) for the detection of the intrathecal humoral response and MS diagnosis in order to optimize the Laboratory investigation in this context. This evidence concerns the gene CXCL13 and myeloid sarcoma.